CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
PR Newswire•21/09/2026•08:00 ET
0
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study PR Newswire
CAPLYTA(®) significantly reduced the signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3
Get started
Create a free account to read the full story and Whiz Insights.